A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hemat

  • Craddock, Charles (Principal Investigator)

Project Details

Short titleA phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hemat
StatusFinished
Effective start/end date1/01/06 → 31/12/12

Funding

  • Queen Elizabeth Hospital